Watchlist

Watchlist
Aptose Biosciences, Inc. (APTO)
Aptose Biosciences, Inc. (APTO)
Premarket Gainers as of 9:05 am
NCTY +33% on partnership agreement with Gingkoo Technology. More news on: The9 Limited, IZEA Inc., Blackhawk Network Holdings, Inc., Stocks on the move, Read more …
Aptose Biosciences (APTO) Presents At 10th Annual Biotech Showcase 2018 - Slideshow
The following slide deck was published by Aptose Biosciences Inc. in conjunction with this Read more …
Your Daily Pharma Scoop: Portola BLA Review Process Delayed, DelMar Soars, Alexion Gets Nod For Soliris In Japan
Analysis of top Seeking Alpha coverage: Portola Today we will discuss the implications of the delay in the review of Portolas ( PTLA ) AndexXa BLA. The news sent PTLA shares down more than 10% on Tuesday. Portola closed 10.68% lower on Tuesday at $49. Despite the sell-off on Tu…
Premarket Gainers as of 9:05 am
APTO +22% after FDA grants Orphan Drug designation to CG806 in AML. More news on: Aptose Biosciences Inc., Future Fintech Group Inc, LongFin Corp, Stocks on the move, Read more …
FDA grants Orphan Drug designation to Aptose's CG'806 in AML; shares ahead 32% premarket
Aptose Biosciences (NASDAQ: APTO ) announces that the FDA has granted orphan drug designation to CG806 , a highly potent pan-FLT3/pan-BTK inhibitor, for the treatment of patients with acute myeloid leukemia (AML). More news on: Aptose Biosciences Inc., Healthcare stocks news, St…
Your Daily Pharma Scoop: Conatus Looks Undervalued, Teva Announces Restructuring, Bristol-Myers Signs Licensing Agreement
Content Analysis of coverage: CNAT Stocks in the news: TEVA, BMY Analyst Ratings Insider Sales Insider Purchases Earnings Report Secondary Offerings Earnings Calendar Trade Idea of the Day (for TPT subscribers only) Subscriber Questions & Answers…
Aptose Biosciences' (APTO) CEO William Rice on Q3 2017 Results - Earnings Call Transcript
Aptose Biosciences Inc. (APTO) Q3 2017 Earnings Conference Call November 14, 2017 17:00 ET Executives Susan Pietropaolo - Investor Relations William Rice - Chairman, President and Chief Executive Officer Gregory Chow - Senior Vice President and Chief Financial Officer Analysts…
Aptose Biosciences beats by $0.01
Aptose Biosciences (NASDAQ: APTO ): Q3 EPS of -$0.14 beats by $0.01 . Cash and equivalents of $10.9M. Press Release More news on: Aptose Biosciences Inc., Earnings news and commentary, Healthcare stocks news, ,
Aptose Biosciences (APTO) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
The following slide deck was published by Aptose Biosciences Inc. in conjunction with this Read more …
Premarket Gainers as of 9:05 am
RH +40% on lifting FY guidance. More news on: RH, Cleantech Solutions International, Inc., Cabela's Incorporated, Stocks on the move, Read more …
Investment Mistakes - I Have Made My Share
Introduction A reader recently suggested I share some of my most egregious investment-related errors. I was somewhat reluctant at first since I did not want to relive some of these painful experiences. After deliberating for a few days I realized that if I could impart some of my errors/less…
Aptose Biosciences, Inc. (APTO)